Patents by Inventor Carl C. Ward

Carl C. Ward has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Covalent targeting of E3 ligases
    Patent number: 12161648
    Abstract: Disclosed herein, inter alia, are compositions and methods for targeting E3 ligases. In an aspect is a targeted protein degrader including 1) a targeted protein binder and 2) an E3 Ubiquitin ligase binder, wherein the E3 Ubiquitin ligase is human RNF4 or human RNF114. In an aspect is provided a pharmaceutical composition including a compound as described herein, including embodiments, and a pharmaceutically acceptable excipient.
    Type: Grant
    Filed: October 9, 2019
    Date of Patent: December 10, 2024
    Assignees: The Regents of the University of California, Novartis AG
    Inventors: Jessica Spradlin, Carl C. Ward, Daniel K. Nomura, Markus Schirle, John A. Tallarico, Jeffrey McKenna, Thomas John Maimone, Xirui Hu
  • DEUBIQUITINASE-TARGETING CHIMERAS AND RELATED METHODS
    Publication number: 20240252655
    Abstract: Described herein are bifunctional compounds, as well as pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, or tautomers thereof, that function to recruit certain deubiquitinases to a target protein for modulation (e.g., stabilization) of the target protein, as well as methods of use thereof.
    Type: Application
    Filed: April 29, 2022
    Publication date: August 1, 2024
    Inventors: Lydia Boike, Dustin Leard Dovala, Nathaniel James Henning, Matthew James Hesse, Gang Liu, Jeffrey M. McKenna, Daniel K. Nomura, Markus Eberhard Schirle, Jessica Nichole Spradlin, John A. Tallarico, Carl C. Ward, Melissa Pighetti
  • COVALENT TARGETING OF E3 LIGASES
    Publication number: 20210369731
    Abstract: Disclosed herein, inter alia, are compositions and methods for targeting E3 ligases. In an aspect is a targeted protein degrader including 1) a targeted protein binder and 2) an E3 Ubiquitin ligase binder, wherein the E3 Ubiquitin ligase is human RNF4 or human RNF114. In an aspect is provided a pharmaceutical composition including a compound as described herein, including embodiments, and a pharmaceutically acceptable excipient.
    Type: Application
    Filed: October 9, 2019
    Publication date: December 2, 2021
    Inventors: Jessica Spradlin, Carl C. Ward, Daniel K. Nomura, Markus Schirle, John A. Tallarico, Jeffrey McKenna, Thomas John Maimone, Xirui Hu
  • COMPOSITIONS AND METHODS FOR MODULATING PPP2R1A
    Publication number: 20200054651
    Abstract: Disclosed herein, inter alia, are compositions and methods useful for modulating PPP2R1 A and for the treatment of cancer.
    Type: Application
    Filed: February 2, 2018
    Publication date: February 20, 2020
    Inventors: Daniel K. Nomura, Elizabeth A. Moore, Carl C. Ward, Leslie A. Bateman, Tucker R. Huffman, David K. Miyamoto, Jessica Spradlin